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Cystic fibrosis (CF), one of the most commonly diagnosed mono­
genic disorders, has been well researched in many nations. Primarily 
affecting the mucus­secreting organs of the body, such as the lungs, 
pancreas, liver and intestinal tract, no cure has been developed for 
this fatal disorder. Nevertheless, assisted by large­scale research 
efforts and advances in sequencing technologies, several countries, 
including Australia, Belgium, Canada, France, Germany, the UK, The 
Netherlands and the USA, have successfully established CF registries. 
These registries have had a positive impact on the management and 
therefore on the quality of life of patients with CF and have also 
provided benefit in terms of reducing the costs associated with their 
care.[1­3]
In countries in which CF research has been well established and 
where CF registries and/or newborn screening programmes exist, 
median survival rates for patients with CF have increased steadily 
year on year. Currently the median age of survival is 52 years in 
Canada,[4] 42 years in the USA,[5] 40 years in Europe[6] and 27 years in 
Australia.[7] In South Africa (SA), the life expectancy of a CF patient, 
as reported in 2008, was less than 21 years.[8] In comparison, life 
expectancy for Canadian, American, French, British and Australian 
CF patients in the same year was approximately 30, 37, 28, 27 and 
30  years, respectively.[9­13] Westwood[8] also highlighted the difference 
that existed between the median age of death in white individuals 
with CF, i.e. of Caucasian/European descent (25.8 years), and 
patients of mixed race (20.5 years) in the Western Cape Province of 
SA. Nevertheless, very little is known about causative CF variants 
in SA and other African nations.[14,15] This difference is due in part 
to the widespread and incorrect belief that CF only affects ‘white’ 
populations – a notion that is increasingly being shown to be 
incorrect.[16,17]
Consequences of an age-old problem 
and potential solutions
The initial assumption that CF could only affect white South Africans 
was in part based on the observed disparity in mutation detection 
rates between population groups. Variations in mutation detection 
rates have been influenced further by the fact that many CF­causing 
variants are population specific. Currently, more is known about CF 
mutations found in the well­characterised white SA population than 
any of the other affected population groups. As a result, causative 
variants are typically identified in 83% of white SA CF patients, while 
CF­associated variants have previously only been identified in 55% 
and 21% of mixed­race and black SA CF patients, respectively. [18] 
Screening panels initially used to diagnose CF in SA patients were 
based on variants that are common to European populations, and 
while attempts have been made to collect larger numbers of CF 
samples in other patient groups in SA, few publications addressing 
the chasm in variant data exist.
A lack of CF data in non­Caucasoid population groups is common 
to SA and other African countries. There are no patient registries for 
this disease on the African continent, which means that African CF 
patients cannot benefit from clinical interventions planned on the 
basis of trends in registry data. Despite the unparalleled genomic 
diversity that exists in African populations, African genomes have 
been vastly understudied.[19] This is illustrated in patients in whom 
genetic testing returns false­negative results because the CF­causing 
mutations have not been fully characterised in their population(s). In 
some cases, this problem has been resolved through the application of 
gene sequencing methods.[20,21] Adding further complexity to existing 
information is the fact that a significant proportion of reported SA 
CF data were published over 10 years ago (Table 1). Altogether, 
when considering the lack of data and the absence of an SA newborn 
screening programme, making a quick and accurate molecular 
diagnosis of CF is difficult in many cases, and assessing the health 
of the local CF population in order to propose and implement the 
interventions needed to improve prognosis is challenging.
Early detection of CF has repeatedly been shown to be of benefit 
to patients and public healthcare systems.[30,31] For instance, in 2012, 
65%, 63%, and 50% of all new CF cases in Australia, France and The 
Netherlands, respectively, were detected through neonatal screening 
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programmes.[12,32,33] In 2011, neonatal screening accounted for the 
detection of 74% of all new CF cases in the UK.[13] This has been 
highly beneficial, since early detection of CF can reduce negative 
nutritional outcomes, general health complications and decline in 
cognitive capacity, thereby improving the overall health of affected 
patients.[34,35] Early diagnosis has also been shown to provide an 
economic benefit. For example, Dutch patients identified by newborn 
screening programmes spend about a million euros less on treatment 
over the course of their lives than patients not discovered through 
this method.[36] Interestingly, despite the clearly demonstrated benefit 
of early diagnosis, in studies conducted on SA CF patients there is 
no correlation between specific CF variants and the severity of lung 
function decline and associated nutritional status.[37,38]
Based on CF variant data that are currently available, the most 
common CF variants in SA are ΔF508, c.3120+1G>A, c.3272­26A>G 
and 394delTT, which have been identified in 69.8%, 13.2%, 3.4%, 
and 3.0% of screened patients, respectively (Table 2). However, as 
reflected in Table 1, different screening methods were used in the 
detection of these variants. Although not always feasible, especially 
in early studies, it must also be noted that not a single reported 
study has made use of an unbiased DNA sequencing approach. For 
example, many black SA patients are screened only for the presence 
of the c.3120+1G>A variant in order to make a positive molecular 
diagnosis of CF.[17,18,39] Novel or SA­specific mutations in the major 
population groups have therefore gone undiscovered or could not 
have been detected owing to limited screening capacity. An additional 
confounding factor, as illustrated in Table 3, is that SA CF data have 
largely been dominated by white patients, a minority genetic group 
in the country. Although historical factors are largely responsible for 
this phenomenon, access to and the cost of sequencing technology 
now make it possible to obtain new information with relative ease, 
affordability and speed.[40] Use of advanced sequencing methods, 
particularly in majority population groups, would be of benefit to SA 
CF patients, since SA is home to some of the most genetically diverse 
population groups in the world.[41]
A need for more molecular data to assist with accurately 
diagnosing SA and African CF patients therefore exists. Nevertheless, 
as illustrated by existing CF registries, several types of data (and not 
just causative variant information) are investigated. In the absence of 
molecular data, developing algorithms that can aid in the diagnosis of 
CF given limited clinical, biochemical and/or molecular information 
may be invaluable to SA clinicians in the interim. Although such 
programmes/tools are only as good as the quality and quantity of 
available data, they at least have the potential to present baseline 
probabilities as to a positive CF diagnosis. Such tools might easily 
serve as a standard by which potential CF patients could be selected 
for sequencing projects, thereby maximising the odds of identifying 
previously undescribed CF variants. In so doing, more exact data 
could be fed back into diagnostic algorithms to improve their 
accuracy.
Conclusions
The lack of standardised SA CF data is having a negative impact on 
the longevity of SA CF patients. Driving CF research with the distinct 
aims of: (i) identifying CF variants relevant to all SA population 
groups; (ii) establishing and maintaining a country­specific CF 
database/registry; (iii) establishing a solid foundation for a newborn 
screening programme; and (iv) exploring novel means through which 
a positive clinical diagnosis could be made (given limited molecular 
data) would be of great benefit to the overall care received by many 
local patients. The first of these points can be achieved through 
the use of next­generation sequencing methods, whole­exome 
sequencing, and/or targeted sequencing of the CFTR (cystic fibrosis 
transmembrane conductance regulator) gene. Although presenting 
Table 1. Methods employed to detect CF-associated variants in SA CF patients
Authors Publication year Reference Method(s) used to detect CF variant(s)
Denter 1992 22 Selective screening for the ΔF508 variant only
Herbert and Retief 1992 23 Selective screening for the ΔF508 variant only
Osborne et al. 1992 24 Selective screening for the N1303K variant only
Carles et al. 1996 25 PCR, DGGE (exon for exon), and finally direct sequencing of aberrant migrating or 
heteroduplex DGGE bands
Padoa et al. 1999 26 Selective screening for four variants, SSCP analysis to detect an additional 
variant, and sequencing of aberrant bands that indicated the presence of a sixth 
CF­associated allele. This article states that the ΔF508 variant was not found in 
this study, but is unclear whether testing for this variant occurred in the CF and 
suspected CF individuals
Romey et al. 1999 27 DGGE and direct sequencing of the minimal CFTR promotor region. Single region 
studied
Goldman et al. 2003 18 In black SA CF patients: selective screening for c.3120+1G>A, and if not found, 
additionally screened for ΔF508. In coloured SA CF patients: selective screening 
for 24 variants. Five patients screened only for ΔF508. In white SA CF patients: 
Selective screening for 24 variants
Des Georges et al. 2008 28 SQF­PCR and WGA with MLPA in patients whose samples did not undergo WGA
De Carvalho and 
Ramsay
2009 29 MLPA for CNV detection
Masekela et al. 2013 17 Selective screening for the c.3120+1G>A variant in patients in whom either no 
variants or only a single variant had previously been detected. Variant data not 
stratified according to ethnicity and only the c.3120+1G>A variant results reported
CF = cystic fibrosis; SA = South African; PCR = polymerase chain reaction; DGGE = denaturing gradient gel electrophoresis; SSCP = single­strand conformation polymorphism;  
CFTR = cystic fibrosis transmembrane conductance regulator; SQF = semiquantitative fluorescent multiplex; WGA = whole­genome amplification; MLPA = multiplex ligation­dependent  
probe amplification; CNV = copy number variation.
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their own unique challenges, sincere, multidisciplinary collaborative 
efforts that involve stakeholders from academic, private, public and 
government sectors would be able to address the remaining points. [42] 
Together, these changes could ensure a healthier and longer future for 
all SA CF patients.
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